India's medical device regulator, the Central Drugs Standard Control Organisation (CDSCO), is moving to align its framework with international standards. Over the past year, it has published new software guidance, reinforced quality management expectations shared with other major markets, and introduced faster review pathways, changes that increasingly let manufacturers reuse evidence built for other regulatory systems.
New Guidance for Medical Device Software
On July 21, 2026, CDSCO's Medical Devices Division issued final guidance on Medical Device Software (MDSW), covering classification, safety and performance requirements, documentation, quality management, and post market obligations. The guidance was revised from an October 2025 draft after stakeholder feedback, including input from industry bodies such as Nasscom, and it explicitly addresses AI and machine learning based software across its lifecycle, one of the first CDSCO documents to do so directly.
Jul 2026 CDSCO
publishes final Medical Device Software guidance, aligning classification and lifecycle requirements with international norms and addressing AI and machine learning based software directly.
One Quality System, Multiple Markets
CDSCO requires manufacturers to maintain a quality management system aligned with ISO 13485:2016, with software specific expectations increasingly referencing IEC 62304, ISO 14971, and IEC 82304-1, the same standards that underpin FDA, EU MDR, and MDSAP submissions. In practice, this means the QMS evidence base a manufacturer already built for the EU or the US largely serves a CDSCO application too, reducing duplicated compliance work for companies operating across markets. India is also targeting standardized digital submission formats such as eCTD by 2027, a further step toward aligning with how global regulators expect applications to be structured.
Faster Pathways for Innovative Devices
Beyond software, CDSCO introduced a quicker approval route for innovative medical devices under the New Drugs and Clinical Trials (Amendment) Rules, 2025, with review completed within 30 working days at each step. A separate update in January 2026 refreshed the list of CDSCO authorized laboratories for IVD performance evaluation, mapping specific disease categories to designated facilities under the Medical Devices Rules, 2017.
Why This Matters Beyond India
None of these changes make CDSCO identical to EU MDR or FDA review. But the direction is consistent: less duplication for global manufacturers, and evidence built to international standards has more paths to reuse rather than being redone for every market. For companies already weighing India as part of a cross border validation strategy, a regulator actively converging with the standards its evidence is measured against is a meaningfully different starting point than one operating in isolation.
